Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.52 |
| ▸ | ITK | Q08881 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584191 | 1.00 | LRRK2 (0.52) | LRRK2ITKCHUKTTKADORA2A | |
| SCHEMBL7425662 | 0.86 | ITK (0.55) | LRRK2ITKTTKADORA2AADORA2B | |
| SCHEMBL1519585 | 0.82 | ADORA2A (0.42) | LRRK2ITKADORA2AADORA2B | |
| SCHEMBL922865 | 0.80 | JAK2 (0.55) | LRRK2ITKCHUKTTK | |
| SCHEMBL4879865 | 0.79 | ITK (0.48) | LRRK2ITKCHUKTTKL3MBTL1 | |
| SCHEMBL2870356 | 0.79 | ITK (0.50) | LRRK2ITKCHUKTTK | |
| SCHEMBL30548034 | 0.79 | ITK (0.50) | LRRK2ITKCHUKTTK | |
| SCHEMBL13122264 | 0.79 | ITK (0.50) | LRRK2ITKCHUKTTK | |
| SCHEMBL31587042 | 0.79 | ITK (0.50) | LRRK2ITKCHUKTTKL3MBTL1 | |
| SCHEMBL14737930 | 0.79 | ITK (0.50) | LRRK2ITKCHUKTTKL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117402143-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-117069700-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117050062-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20160024007-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150315197-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-05 | — | — | US | disclosed |
| US-7812045-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
| US-6610692-B1 | Anticoagulants | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315197-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | LRRK2 935/4885ITK 3781/4885CHUK 1844/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | LRRK2 2675/4885ITK 1248/4885CHUK 694/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | LRRK2 2675/4885ITK 1248/4885CHUK 694/4885 |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | LRRK2 344/4885ITK 558/4885CHUK 4/4885 |
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | LRRK2 2798/4885ITK 631/4885CHUK 3896/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | LRRK2 3971/4885ITK 4178/4885CHUK 794/4885 |
| US-20160024007-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | CLN6, ALDH1A2, C1S | LRRK2 829/4885ITK 4740/4885CHUK 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.